Announcements
Sidley Represents Valius Sciences in Financing Raising More Than US$10 Million for Future Cancer Diagnostics
April 23, 2026
Sidley represented Valius Sciences, a San Francisco-based healthcare diagnostics company focused on cancer treatment, in a Series Seed financing round that raised more than US$10 million. The round was led by 8VC and Basis Set Ventures.
More information about the transaction can be found here.
The Sidley team was led by Michael Podolny (Emerging Companies and Venture Capital) and included Daniel Wei (Emerging Companies and Venture Capital) and Laura DeMassa (M&A).
Contacts
Capabilities
Suggested News & Insights
2026 Emerging Companies & Venture Capital SummitWednesday, May 20, 2026New U.S. SEC Exemptive Order on Tender Offers Will Meaningfully Streamline Certain Liquidity TransactionsApril 21, 2026Sidley Represents Galera Therapeutics in Its Merger With Obsidian Therapeutics and US$350 Million Private Placement FinancingApril 21, 2026Sidley Represents Neomorph in Its US$100 Million Series B FinancingApril 15, 2026SEC Releases Landmark Interpretation on Application of U.S. Securities Laws to Crypto Assets, in Coordination With CFTCMarch 24, 2026Sidley Represents Crossbow Therapeutics in US$77 Million Series B FinancingMarch 18, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory